AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 81.9%, against 81.1% the year before. The highest annual figure on record is 82.1% in fiscal 2016.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 81.9% | +0.8 |
| FY2024 | Dec 31, 2024 | 81.1% | −0.8 |
| FY2023 | Dec 31, 2023 | 82.0% | +9.9 |
| FY2022 | Dec 31, 2022 | 72.1% | +5.3 |
| FY2021 | Dec 31, 2021 | 66.8% | −13.3 |
| FY2020 | Dec 31, 2020 | 80.1% | +0.3 |
| FY2019 | Dec 31, 2019 | 79.8% | +2.2 |
| FY2018 | Dec 31, 2018 | 77.7% | −3.1 |
| FY2017 | Dec 31, 2017 | 80.8% | −1.3 |
| FY2016 | Dec 31, 2016 | 82.1% | +0.9 |
| FY2015 | Dec 31, 2015 | 81.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 83.6% | +11.4 |
| Q2 FY2025 | Jun 30, 2025 | 82.9% | +9.5 |
| Q2 FY2024 | Jun 30, 2024 | 83.1% | −1.2 |
| Q2 FY2023 | Jun 30, 2023 | 82.8% | +1.1 |
| Q2 FY2022 | Jun 30, 2022 | 72.2% | −8.2 |
| Q2 FY2021 | Jun 30, 2021 | 73.3% | −9.7 |
| Q2 FY2020 | Jun 30, 2020 | 84.3% | – |
| Q2 FY2019 | Jun 30, 2019 | 81.7% | – |
| Q2 FY2018 | Jun 30, 2018 | 80.4% | – |
| Q2 FY2017 | Jun 30, 2017 | 83.0% | – |
See a number that looks wrong?